|Bid||1,295.00 x 175400|
|Ask||1,315.00 x 417900|
|Day's range||1,296.00 - 1,309.00|
|52-week range||1,236.40 - 1,724.50|
|PE ratio (TTM)||41.85|
|Earnings date||25 Apr 2018|
|Forward dividend & yield||0.80 (6.15%)|
|1y target est||1,522.48|
GlaxoSmithKline Plc estimates Brexit-related costs as high as 70 million pounds ($98 million) over the next two to three years as Britain’s largest drugmaker seeks to maintain a steady supply of products ...
** Adaptimmune up 30 percent on news that second solid tumour type responds to its cell therapy, boosting hopes for biotech company's NY-ESO SPEAR T-cells partnered with GlaxoSmithKline ** Adaptimmune ...
Hikma Pharmaceuticals Plc (Frankfurt: A0HG69 - news) is expected to cut more jobs in its generics business to save costs, the Jordan-based drugmaker said on Wednesday, after reporting full-year profit and revenue largely in line with expectations. Hikma, which was forced to cut revenue guidance for its generics business three times in 2017 due to pricing pressures in the United States, has cut 200 jobs since it bought the business from Boehringer Ingelheim in 2016, CFO Khalid Nabilsi said in a call to Reuters. Nabilsi added that another 200 jobs would go as a result of the consolidation of its generics' manufacturing facilities and U.S. distribution centres.
GlaxoSmithKline Plc, the only major drugmaker led by a woman, has one of the smallest gender pay gaps reported at large U.K. companies so far.
** Shares of Hikma Pharmaceutical fall 6 pct at open, now down 2 pct, with Vectura down 5.3 pct ** Hikma fails to find quick resolution in dispute with U.S. FDA over plans to launch a generic copy of GlaxoSmithKline's ...
The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura (VEC.L), said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well. Shares in Hikma fell 1 percent in early trade, while Vectura lost 5 percent.
GlaxoSmithKline (Other OTC: GLAXF - news) has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals (Frankfurt: A0HG69 - news) conduct a further clinical study evaluating its generic version of the drug. The Jordan-based firm said on Monday it expected to submit a response to the U.S. Food and Drug Administration (FDA) with new clinical data in 2019. Hikma's partner on the project, Vectura, said this meant a potential approval and launch of the generic inhaled medication could come in 2020 if all goes well.
Reckitt Benckiser (Xetra: A0M1W6 - news) has no regrets about its $17 billion acquisition of Mead Johnson last year, its chief executive said, even though there are concerns it may now be too stretched to buy Pfizer's coveted consumer health business. The Pfizer business, which is currently on the block, would fulfil Reckitt CEO Rakesh Kapoor's long-stated plan to transform Reckitt from a British maker of household cleaning products into a global leader in consumer healthcare.
Reckitt Benckiser (RB.L) has no regrets about its $17 billion (12.3 billion pounds) acquisition of Mead Johnson last year, its chief executive said, even though there are concerns it may now be too stretched to buy Pfizer's (PFE.N) coveted consumer health business. The Pfizer business, which is currently on the block, would fulfil Reckitt CEO Rakesh Kapoor's long-stated plan to transform Reckitt from a British maker of household cleaning products into a global leader in consumer healthcare.
While the U.S. stock markets appear overheated, savvy investors can find more value in the international markets, particularly Europe, where stocks remain cheap. We asked five top advisors and MoneyShow.com contributors to highlight favorite stocks. They came back with seven picks.
Key announcements include the failure of Dermira's (DERM) acne candidate in two pivotal late-stage studies and Merck's oncology collaboration with Japan's Eisai.
GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-acting β2-agonist.
LONDON & BRISBANE, Calif.--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of ...
Glaxo (GSK) presents data from OSMO study on a new respiratory medicine, Nucala, and on INSPIRING, a phase IIIb study on investigational HIV candidate dolutegravir at medical conferences.
GlaxoSmithKline Plc has seen precious few takers for its $730,000 gene therapy for a rare and life-threatening immune illness known as “bubble-boy disease.” Now a tiny startup thinks it can succeed where ...
This year’s deadly season has given drugmakers a sense of urgency in the war on the ever-mutating influenza virus.
Endo Pharmaceuticals Inc. and GlaxoSmithKline LLC agreed to settle lawsuits accusing the drugmakers of hiding the health risks of a testosterone-boosting drug marketed to middle-aged men, according to ...
The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, ...